CO2019008390A2 - Uso de biomarcadores en la identificación de pacientes con cáncer que serán sensibles al tratamiento con un inhibidor de prmt5. - Google Patents
Uso de biomarcadores en la identificación de pacientes con cáncer que serán sensibles al tratamiento con un inhibidor de prmt5.Info
- Publication number
- CO2019008390A2 CO2019008390A2 CONC2019/0008390A CO2019008390A CO2019008390A2 CO 2019008390 A2 CO2019008390 A2 CO 2019008390A2 CO 2019008390 A CO2019008390 A CO 2019008390A CO 2019008390 A2 CO2019008390 A2 CO 2019008390A2
- Authority
- CO
- Colombia
- Prior art keywords
- sensitive
- treatment
- biomarkers
- identification
- cancer patients
- Prior art date
Links
- 229940125897 PRMT5 inhibitor Drugs 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000000090 biomarker Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000004075 alteration Effects 0.000 abstract 3
- 239000004475 Arginine Substances 0.000 abstract 1
- 101710167853 N-methyltransferase Proteins 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Primary Health Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un método de identificación de un paciente que es probable que sea sensible al tratamiento con un inhibidor de proteína arginina N-metiltransferasa 5 (PRMT5) que comprende: Evaluar una muestra biológica del paciente para detectar la presencia de una alteración del espliceosoma, en el que la presencia de cualquiera de dicha alteración indica una mayor probabilidad de que dicho paciente sea sensible al tratamiento con dicho inhibidor de PRMT5 que en ausencia de cualquiera de dicha mutación o alteración.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762464006P | 2017-02-27 | 2017-02-27 | |
PCT/EP2018/054644 WO2018154104A1 (en) | 2017-02-27 | 2018-02-26 | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019008390A2 true CO2019008390A2 (es) | 2019-08-20 |
Family
ID=61563368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0008390A CO2019008390A2 (es) | 2017-02-27 | 2019-07-31 | Uso de biomarcadores en la identificación de pacientes con cáncer que serán sensibles al tratamiento con un inhibidor de prmt5. |
Country Status (22)
Country | Link |
---|---|
US (1) | US11279970B2 (es) |
EP (1) | EP3585904B1 (es) |
JP (1) | JP7225106B2 (es) |
KR (1) | KR102573149B1 (es) |
CN (1) | CN110382707A (es) |
AU (1) | AU2018225312B2 (es) |
BR (1) | BR112019017466A2 (es) |
CA (1) | CA3049739A1 (es) |
CL (1) | CL2019002438A1 (es) |
CO (1) | CO2019008390A2 (es) |
EA (1) | EA201992026A1 (es) |
IL (1) | IL268842B1 (es) |
JO (1) | JOP20190199B1 (es) |
MA (1) | MA47594A (es) |
MX (1) | MX2019010150A (es) |
MY (1) | MY195860A (es) |
PE (1) | PE20191359A1 (es) |
PH (1) | PH12019501942A1 (es) |
SG (1) | SG11201907607VA (es) |
TN (1) | TN2019000212A1 (es) |
UA (1) | UA127679C2 (es) |
WO (1) | WO2018154104A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202321249A (zh) | 2015-08-26 | 2023-06-01 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
EA201892031A1 (ru) | 2016-03-10 | 2019-02-28 | Янссен Фармацевтика Нв | Замещенные аналоги нуклеозидов для применения в качестве ингибиторов prmt5 |
CA3037998A1 (en) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
JP7225106B2 (ja) | 2017-02-27 | 2023-02-20 | ヤンセン ファーマシューティカ エヌ.ベー. | Prmt5阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用 |
EP3720495A4 (en) * | 2017-12-05 | 2021-06-02 | Angex Pharmaceutical, Inc. | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS |
KR20200097280A (ko) | 2017-12-08 | 2020-08-18 | 얀센 파마슈티카 엔.브이. | 신규 스피로바이사이클릭 유사체 |
IL262658A (en) * | 2018-10-28 | 2020-04-30 | Memorial Sloan Kettering Cancer Center | Prevention of age related clonal hematopoiesis and diseases associated therewith |
AU2020256166A1 (en) | 2019-04-02 | 2021-10-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
GB201905780D0 (en) | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用prmt5抑制劑治療癌症之方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4224438A (en) | 1970-07-14 | 1980-09-23 | Boehringer Mannheim Gmbh | Adenosine-5'-carboxylic acid amides |
US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
CN1331326A (zh) * | 2000-06-30 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——人精氨酸甲基转移酶(hrmt)32.12和编码这种多肽的多核苷酸 |
WO2003039523A2 (en) | 2001-11-05 | 2003-05-15 | Exiqon A/S | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES |
US7034147B2 (en) | 2001-11-29 | 2006-04-25 | Irm Llc | Nucleoside analog libraries |
MXPA04008008A (es) | 2002-02-19 | 2005-03-23 | Cv Therapeutics Inc | Agonistas parciales y completos de receptores de adenosina a1. |
US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
JPWO2005005450A1 (ja) | 2003-07-15 | 2006-08-24 | 三井化学株式会社 | 環状ビスジヌクレオチドの合成方法 |
CA2548283A1 (en) | 2003-12-19 | 2005-07-21 | Koronis Pharmaceuticals, Inc. | Mutagenic heterocycles |
WO2006078752A2 (en) | 2005-01-21 | 2006-07-27 | Methylgene, Inc. | Inhibitors of dna methyltransferase |
US20110159111A1 (en) | 2006-06-29 | 2011-06-30 | Astex Therapeutics Limited | Pharmaceutical combinations |
US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
CA2737661C (en) | 2008-09-23 | 2019-08-20 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
US8323918B2 (en) * | 2008-12-12 | 2012-12-04 | University Of South Carolina | Chloroacetamidine based inhibitors and activity based probes for the protein arginine methytransferases |
EP2513298A4 (en) | 2009-12-18 | 2013-03-27 | Harvard College | COMPOUNDS PROMOTING BETA CELL REPLICATION AND METHODS OF USE THEREOF |
RU2013130253A (ru) | 2010-12-03 | 2015-01-10 | Эпизайм, Инк. | 7-деазапуриновые регуляторы метилтрансферазы гистонов и способы их применения |
CA2819620A1 (en) | 2010-12-03 | 2012-06-21 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
MX2013006951A (es) | 2010-12-16 | 2013-10-03 | Abbvie Inc | Compuestos antivirales. |
ES2587512T3 (es) | 2011-04-04 | 2016-10-25 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Derivados de 2'-O-aminooximetil nucleósido para su uso en la síntesis y modificación de nucleósidos, nucleótidos y oligonucleótidos |
US20150057243A1 (en) | 2012-04-02 | 2015-02-26 | Northern University | Compositions and Methods for the Inhibition of Methyltransferases |
WO2014035140A2 (en) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
US20140100184A1 (en) | 2012-08-31 | 2014-04-10 | Baylor College Of Medicine | Selective inhibitors of histone methyltransferase dot1l |
WO2014100730A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
EA027908B1 (ru) | 2012-12-21 | 2017-09-29 | Эпизим, Инк. | Ингибиторы prmt5 и их применения |
EP2935241A1 (en) | 2012-12-21 | 2015-10-28 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
EP2935240A1 (en) | 2012-12-21 | 2015-10-28 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
US10087151B2 (en) | 2014-01-09 | 2018-10-02 | The J. David Gladstone Institutes, A Testimentary Trust Established Under The Will Of J. David Gladstone | Substituted benzoxazine and related compounds |
US20170198006A1 (en) | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
CR20170021A (es) | 2014-07-01 | 2017-04-04 | Millennium Pharm Inc | Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo |
CR20170384A (es) | 2015-02-24 | 2017-11-16 | Pfizer | Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos |
TW202321249A (zh) | 2015-08-26 | 2023-06-01 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
CN108884108B (zh) | 2016-03-10 | 2021-08-31 | 詹森药业有限公司 | 用于用作prmt5抑制剂的取代核苷类似物 |
EA201990851A1 (ru) | 2017-02-24 | 2019-09-30 | Янссен Фармацевтика Нв | Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5 |
JP7225106B2 (ja) | 2017-02-27 | 2023-02-20 | ヤンセン ファーマシューティカ エヌ.ベー. | Prmt5阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用 |
-
2018
- 2018-02-26 JP JP2019545251A patent/JP7225106B2/ja active Active
- 2018-02-26 CN CN201880013998.5A patent/CN110382707A/zh active Pending
- 2018-02-26 CA CA3049739A patent/CA3049739A1/en active Pending
- 2018-02-26 JO JOP/2019/0199A patent/JOP20190199B1/ar active
- 2018-02-26 US US16/487,852 patent/US11279970B2/en active Active
- 2018-02-26 TN TNP/2019/000212A patent/TN2019000212A1/en unknown
- 2018-02-26 EA EA201992026A patent/EA201992026A1/ru unknown
- 2018-02-26 KR KR1020197024211A patent/KR102573149B1/ko active IP Right Grant
- 2018-02-26 SG SG11201907607VA patent/SG11201907607VA/en unknown
- 2018-02-26 AU AU2018225312A patent/AU2018225312B2/en active Active
- 2018-02-26 BR BR112019017466-4A patent/BR112019017466A2/pt unknown
- 2018-02-26 IL IL268842A patent/IL268842B1/en unknown
- 2018-02-26 MX MX2019010150A patent/MX2019010150A/es unknown
- 2018-02-26 EP EP18708634.3A patent/EP3585904B1/en active Active
- 2018-02-26 MA MA047594A patent/MA47594A/fr unknown
- 2018-02-26 MY MYPI2019004748A patent/MY195860A/en unknown
- 2018-02-26 WO PCT/EP2018/054644 patent/WO2018154104A1/en active Application Filing
- 2018-02-26 PE PE2019001538A patent/PE20191359A1/es unknown
- 2018-02-26 UA UAA201910005A patent/UA127679C2/uk unknown
-
2019
- 2019-07-31 CO CONC2019/0008390A patent/CO2019008390A2/es unknown
- 2019-08-22 PH PH12019501942A patent/PH12019501942A1/en unknown
- 2019-08-23 CL CL2019002438A patent/CL2019002438A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL268842A (en) | 2019-10-31 |
EA201992026A1 (ru) | 2020-01-24 |
AU2018225312A1 (en) | 2019-07-25 |
JOP20190199B1 (ar) | 2023-09-17 |
IL268842B1 (en) | 2024-05-01 |
JP7225106B2 (ja) | 2023-02-20 |
US11279970B2 (en) | 2022-03-22 |
JOP20190199A1 (ar) | 2019-08-27 |
EP3585904C0 (en) | 2023-11-29 |
PE20191359A1 (es) | 2019-10-01 |
MA47594A (fr) | 2020-01-01 |
KR20190122677A (ko) | 2019-10-30 |
JP2020508048A (ja) | 2020-03-19 |
SG11201907607VA (en) | 2019-09-27 |
BR112019017466A2 (pt) | 2020-03-31 |
MY195860A (en) | 2023-02-24 |
CL2019002438A1 (es) | 2019-11-29 |
EP3585904B1 (en) | 2023-11-29 |
US20200010881A1 (en) | 2020-01-09 |
TN2019000212A1 (en) | 2021-01-07 |
MX2019010150A (es) | 2019-10-21 |
CN110382707A (zh) | 2019-10-25 |
KR102573149B1 (ko) | 2023-08-30 |
UA127679C2 (uk) | 2023-11-29 |
US20220205026A1 (en) | 2022-06-30 |
WO2018154104A1 (en) | 2018-08-30 |
AU2018225312B2 (en) | 2024-02-08 |
EP3585904A1 (en) | 2020-01-01 |
PH12019501942A1 (en) | 2020-06-29 |
CA3049739A1 (en) | 2018-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019008390A2 (es) | Uso de biomarcadores en la identificación de pacientes con cáncer que serán sensibles al tratamiento con un inhibidor de prmt5. | |
AR102345A1 (es) | Uso de paneles del gen mutante del fgfr en la identificación de pacientes de cáncer que serán sensibles al tratamiento con un inhibidor del fgfr | |
ES2570380T3 (es) | Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento | |
MX2020001575A (es) | Materiales y métodos para evaluar y tratar el cáncer. | |
CL2017003069A1 (es) | Métodos para diagnosticar y tratar el cáncer. | |
BR112017018008A2 (pt) | ?métodos de prognóstico e/ou diagnóstico do câncer, para determinação da dosagem de um produto, para adaptar a dosagem de um produto, para determinar os efeitos benéficos e/ou adversos de uma substância, para identificar um paciente como respondedor a um tratamento, para identificar um paciente como não respondedor a um tratamento, para tratar o câncer, meios para prognosticar e/ou diagnosticar, kit, uso dos meios e dispositivo para a identificação de câncer? | |
BR112018069849A2 (pt) | kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático | |
ES2660149T3 (es) | Identificación, evaluación y terapia de cánceres con resistencia innata o adquirida a inhibidores de ALK | |
BR112014018331A8 (pt) | Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação | |
BR112016029521A2 (pt) | ?kit, dispositivo e método para a detecção de câncer de estômago? | |
AR099883A1 (es) | Computadora y métodos relacionados con el diagnóstico de cáncer de próstata | |
SV2017005459A (es) | Uso de los inhibidores de pan fgfr y método para identificación de pacientes con cáncer elegibles para el tratamiento con un inhibidor de pan fgfr | |
CO2019002607A2 (es) | Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activación por contacto | |
BR112018009463A8 (pt) | ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia | |
BR112018010764A2 (pt) | método para detectar atividade bacteriana em uma amostra biológica e unidade de detecção correspondente | |
AR094873A1 (es) | Métodos y composiciones para detectar y tratar mutantes de akt resistentes a fármacos | |
PT109877A (pt) | Método ótico para a medição da concentração de oxigénio em sistemas de combustível. | |
CO2019002599A2 (es) | Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto | |
PL406989A1 (pl) | Profil mikro RNA we krwi jako test wykrywania raka płuca | |
BR112018070547A2 (pt) | agonistas de rara para o tratamento de aml e mds | |
BR112014027413A2 (pt) | biomarcadores para terapia com inibidor de iap | |
AR117708A1 (es) | Procedimiento in vitro para la detección de disbiosis intestinal aviar | |
MX2020006673A (es) | Metodos de tratamiento del cancer mediante el uso de un inhibidor de ataxia-telangiectasia mutada y rad3 (atr). | |
EA202090439A1 (ru) | Способы и материалы для оценки и лечения рака | |
AR088363A1 (es) | MATERIALES Y METODOS PARA LA DETECCION DEL EVENTO pDAB4472-1606 QUE CONTIENE EL GEN ARILOXIALCANOATO DIOXIGENASA (AAD-12) EN PLANTAS |